A CRO, or contract research organization, is a company that pharmaceutical and biotech firms hire to handle some or all of their drug development work. Rather than building every capability in-house, a drug company (called the “sponsor”) contracts with a CRO to run clinical trials, conduct laboratory testing, manage regulatory filings, or perform other research tasks. It’s outsourcing, but for the highly specialized, heavily regulated world of bringing a new drug to market.
The CRO industry was valued at roughly $41 billion in 2024 and is projected to reach $63 billion by 2030. That growth reflects a broader shift: between 2014 and 2022, spending on contract research and manufacturing organizations grew about 13 percent annually, outpacing the 8 percent growth rate of overall pharmaceutical R&D spending. In practical terms, drugmakers are relying on outside partners more than ever.
What a CRO Actually Does
CROs can be involved at nearly every stage of getting a drug from the lab to the pharmacy shelf. The range of services breaks down into a few broad categories.
Preclinical work happens before a drug is ever tested in humans. CROs in this space run toxicology studies to determine whether a compound is safe enough to move forward, pharmacokinetic studies that track how a drug is absorbed and cleared by the body, and animal model testing required by regulators like the FDA.
Clinical trials are the most visible part of what CROs do. This includes designing trial protocols, recruiting and enrolling patients, monitoring study sites, collecting and analyzing data, and reporting results. A large CRO might manage a Phase III trial spanning dozens of countries and thousands of patients, coordinating everything from local regulatory approvals to shipping investigational drugs to each site.
Regulatory and submission support covers the paperwork side of drug development. CROs help sponsors compile the massive data packages that agencies like the FDA and EMA require before approving a new drug. This includes statistical analysis, medical writing, and managing the back-and-forth communication with regulators.
Post-approval services continue after a drug reaches the market. These include safety monitoring (pharmacovigilance), real-world evidence studies, and additional trials that regulators sometimes require after approval.
Why Drug Companies Outsource to CROs
The economics are straightforward. Running a global clinical trial requires infrastructure that most companies, especially smaller biotech firms, don’t have and can’t afford to build. A CRO already has the staff, the technology platforms, the relationships with clinical trial sites around the world, and the regulatory expertise across multiple countries. Hiring a CRO lets a sponsor access all of that without maintaining it year-round.
Cost efficiency is one factor, but speed matters just as much. CROs that specialize in a therapeutic area, say oncology or rare diseases, often have established networks of investigators and patient databases that can dramatically shorten the time it takes to enroll a trial. For a sponsor racing to get a drug to market before a patent window closes or a competitor launches, those months matter.
There’s also a flexibility argument. Pharmaceutical R&D is inherently unpredictable. A company might need 200 clinical monitors for a Phase III trial and then need almost none for two years. CROs let sponsors scale their workforce up and down without the burden of hiring and layoffs.
Full-Service vs. Functional Outsourcing
Not all CRO relationships look the same. The two main models are full-service outsourcing and functional service provision (FSP), and the distinction comes down to who controls what.
In a full-service model, the CRO takes end-to-end responsibility for trial delivery under a single project management structure. The sponsor hands off a defined scope of work, and the CRO runs it using its own systems, processes, and teams. The appeal is simplicity: one point of accountability, one set of deliverables. The trade-off is less direct control for the sponsor. If priorities shift mid-trial, changes can be slower to implement.
In an FSP model, the sponsor outsources specific roles or functions (data management, biostatistics, clinical monitoring) while keeping tighter control over how the work gets done day to day. FSP staff often work within the sponsor’s own tools and follow the sponsor’s processes, essentially acting as an extension of the in-house team. This gives the sponsor more flexibility and consistency across multiple studies, but it demands stronger internal management to coordinate everything.
The choice between these models typically depends on the sponsor’s size, internal capabilities, and how many trials they’re running simultaneously. A small biotech with one drug in development often benefits from a full-service partner. A large pharma company running 30 trials across five therapeutic areas might prefer the FSP approach for certain functions while using full-service CROs for specific programs.
Regulatory Standards CROs Must Follow
CROs are bound by the same regulatory standards as the sponsors who hire them. The most important is Good Clinical Practice (GCP), an international standard that governs how clinical trials are designed, conducted, recorded, and reported. GCP exists to protect the rights and safety of trial participants and to ensure the resulting data is credible enough for regulatory agencies to act on.
The GCP guidelines, developed through the International Council for Harmonisation (ICH), create a unified standard accepted by regulators in the U.S., Europe, and Japan. When a sponsor delegates trial-related duties to a CRO, the sponsor remains ultimately responsible for the quality and integrity of the data. But the CRO is expected to demonstrate GCP competency among its staff, maintain rigorous quality assurance systems, and preserve data integrity throughout the trial.
Regulatory agencies can and do inspect CRO operations. A CRO that fails an FDA inspection can jeopardize not just one trial but every program it’s running, which is why quality systems and standard operating procedures are central to how these companies operate.
How Sponsors Choose a CRO
Selecting a CRO is one of the highest-stakes decisions in drug development because a poor choice can delay a program by years. The NIH publishes evaluation guidance that outlines the key criteria sponsors typically weigh:
- Therapeutic expertise: Does the CRO have a track record in the specific disease area? A CRO experienced in cardiovascular trials may not be the right fit for a gene therapy program.
- Phase-specific experience: Running a small Phase I safety study in healthy volunteers is fundamentally different from managing a 10,000-patient Phase III outcomes trial. Sponsors look for proven experience in the relevant phase.
- Global reach: If a trial needs to enroll patients across 15 countries, the CRO needs local regulatory knowledge, established site relationships, and familiarity with international requirements in each jurisdiction.
- Staff qualifications: Sponsors evaluate whether the CRO’s team has demonstrated GCP training and relevant scientific credentials.
- Financial stability: A CRO that runs into financial trouble mid-trial creates serious continuity risks. Sponsors look for transparency around fee structures and evidence of organizational stability.
- Risk management: How has the CRO handled unexpected problems in past trials? Delays, safety signals, and regulatory inquiries are inevitable in drug development, and the response matters more than the problem itself.
- Quality assurance: Sponsors want to understand the CRO’s framework for preserving data integrity, its standard operating procedures, and its history with regulatory inspections.
References and past performance round out the evaluation. Sponsors routinely ask whether a CRO has had prematurely terminated trials and request case studies from similar programs. For a relationship that might last five to seven years and involve hundreds of millions of dollars, the due diligence process is extensive.
The Largest CROs in the Industry
The CRO market includes hundreds of companies ranging from small, niche firms specializing in a single therapeutic area to global organizations employing tens of thousands of people. The largest players, including IQVIA, Covance (now part of Labcorp), PPD (acquired by Thermo Fisher Scientific), Syneos Health, and Parexel, operate across all phases of development and in dozens of countries. These full-service giants handle everything from early-stage lab work through post-market surveillance.
At the other end of the spectrum, smaller CROs carve out niches in areas like rare diseases, medical devices, or specific geographic regions where their specialized knowledge gives them an edge over larger competitors. Many sponsors work with multiple CROs simultaneously, matching each partner’s strengths to the specific needs of each program.